Does differing metabolism by cytochrome P450 have clinical importance?
- 1 December 2000
- journal article
- review article
- Published by Springer Nature in Current Atherosclerosis Reports
- Vol. 2 (1) , 14-19
- https://doi.org/10.1007/s11883-000-0090-4
Abstract
The cytochrome P450 (CYP) is a group of enzymes that oxidatively modify drugs to a more water-soluble form for renal excretion. Nearly 50% of all clinically used medications and endogenous steroids are metabolized by the CYP enzyme 3A4, which explains why many of the important potential drug interactions involved this enzyme. Despite an excellent safety record, CYP 3A4 statins (lovastatin, simvastatin, atorvastatin) taken concomitantly with a potent CYP 3A4 inhibitor may increase the risk for adverse events (myopathy, rhabdomyolysis). This article describes the clinical significance of CYP metabolism as the pathways relate to the use of statins, including brief discussions on statins, fibrates, cyclosporine, and calcium channel blockers. In light of these potential interactions, continued vigilance by physicians is necessary to ensure the safe use of statins.Keywords
This publication has 35 references indexed in Scilit:
- Concomitant use of cytochrome P450 3A4 inhibitors and simvastatinThe American Journal of Cardiology, 1999
- Rational Assessment of the Interaction Profile of Cerivastatin Supports its Low Propensity for Drug InteractionsDrugs, 1998
- Combination of Pravastatin and Cyclosporin in Transplant PatientsClinical Pharmacokinetics, 1997
- INFLUENCE OF PHARMACOGENETICS ON DRUG DISPOSITION AND RESPONSEClinical and Experimental Pharmacology and Physiology, 1996
- Naringin and naringenin are not the primary CYP3A inhibitors in grapefruit juiceLife Sciences, 1996
- Rhabdomyolysis from the Coadministration of Lovastatin and the Antifungal Agent ItraconazoleNew England Journal of Medicine, 1995
- SAFETY AND EFFICACY OF LOW DOSE SIMVASTATIN IN CARDIAC TRANSPLANT RECIPIENTS TREATED WITH CYCLOSPORINETransplantation, 1994
- Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemiaThe American Journal of Cardiology, 1994
- Low-dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantationInternational Journal of Cardiology, 1991
- Rhabdomyolysis and Renal Injury With Lovastatin UsePublished by American Medical Association (AMA) ,1988